Prostate Cancer Treatment Response Activated by Skin Disease Immunotherapy

Scientists in the U.K., Switzerland, and Italy have shown how a type of immunotherapy that is undergoing trials for treating psoriasis also renders advanced prostate cancer responsive to hormone therapy. The researchers’ studies in human tissue and in a mouse model found that castration-resistant prostate cancer (CRCP) is driven by interleukin-23 (IL-23) produced by immune cells called myeloid-derived suppressor cells (MDSCs). Treating mice with androgen deprivation therapy (ADT)-resistant